Although gefitinib could restore NKG2D receptor-ligand interactions between NK cells and human lung cancer cells, and inhibit stat3 expression, further molecular mechanisms should be investigated on the difference between A549 and H1975 to the sensitivity to gefitinib-mediated NK cells response. Here, STAT3 is linked to lung carcinoma.